Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Judit Liaño-PonsDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0001-8097-4750
Elisa Garde-LapidoDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0009-0001-5321-1253
Fenja L FahrigDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0009-0008-9040-5752
Merle JäckeringDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0009-0003-9519-2120
Ye YuanDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Stina AnderssonDivision of Pediatrics, Department of Clinical Sciences, Lund University, Lund SE-221 45, Sweden.ORCID 0000-0003-3226-4740
Lea SchortDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Maria EsteveDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0003-2299-9153
Sofie MohlinDivision of Pediatrics, Department of Clinical Sciences, Lund University, Lund SE-221 45, Sweden.ORCID 0000-0002-2458-3963
Oscar C Bedoya-ReinaDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm SE-171 77, Sweden.ORCID 0009-0001-1703-2258
Marie Arsenian-HenrikssonDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0001-6376-7792
Funding
Barncancerfonden (Swedish Childhood Cancer Foundation) PR2021-0129Barncancerfonden (Swedish Childhood Cancer Foundation) PR2021-0131Barncancerfonden (Swedish Childhood Cancer Foundation) TJ2021-0137Cancerfonden (Swedish Cancer Society) 19 0510PjCancerfonden (Swedish Cancer Society) 22 0539 01 HCancerfonden (Swedish Cancer Society) 22 2266PjKarolinska Institutet (KI) 2022-00616Karolinska Institutet (KI) 2022-01805 and 2024-02987Karolinska Institutet (KI) 2022-01925Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet) 19 1073Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet) 22 1031Sigurd and Elsa Goljes Memorial Fund LA2021-0104 and LA2023-0120Vetenskapsrådet (VR) 2018-02580
6 · The paper itself
Abstract
Neuroblastoma (NB) is a heterogeneous childhood cancer, characterized by the amplification of the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment. · full record | Socratic